Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
In this phase III study, the primary objective is to test with a one-sided significance of 5% whether for the treatment of small cell lung cancer (SCLC) patients, brain MRI surveillance alone is non-inferior in terms of overall…
- Trial name
- PRIMALung (NCT04790253)
- Testing
- Prophylactic cranial irradiation
- Where
- 55 sites in Austria, Belgium and 7 more
- Volunteers
- 600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gynecologic Cancer
Follow-up in Gynecological Cancer Survivors
A cross-sectional prospective study of follow-up in gynecologic cancer patients after primary treatment
- Trial name
- NCT03515993
- Where
- 21 sites in Austria, Belgium and 7 more
- Volunteers
- 1,100 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Retroperitoneal Sarcoma, Liposarcoma
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS…
- Conditions
- Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
- Trial name
- STRASS2 (NCT04031677)
- Testing
- Surgery, Preoperative chemotherapy
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 250 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
ER-positive Breast Cancer, HER2-negative Breast Cancer
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
This is an international, multi-center, randomised, open label, superiority phase III trial of elacestrant vs standard endocrine therapy in patients with ER+/HER2- breast cancer and ctDNA relapse.
- Conditions
- ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
- Trial name
- TREAT ctDNA (NCT05512364)
- Testing
- Elacestrant, Tamoxifen, Letrozole 2.5mg
- Where
- 113 sites in Belgium, Cyprus and 10 more
- Volunteers
- 220 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
IDH-mutant Grade 2 or 3 Astrocytoma
Vorasidenib Maintenance for IDH Mutant Astrocytoma
The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared to placebo in patients with IDH-mutant, CNS5 WHO Grade 2 or 3…
- Trial name
- VIGOR (NCT06809322)
- Testing
- Vorasidenib
- Where
- 59 sites in Australia, Austria and 10 more
- Volunteers
- 468 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Hodgkin Lymphoma
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced stage Hodgkin Lymphoma (HL) patients treated…
- Trial name
- COBRA (NCT03517137)
- Testing
- Brentuximab Vedotin, Adriamycin, Vinblastine
- Where
- 16 sites in Belgium, Denmark and 5 more
- Volunteers
- 150 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-Muscle Invasive Bladder Cancer
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
Standard treatment for patients with high-risk NMIBC (high-grade Ta, CIS, or any T1) consists of intravesical Bacillus Calmette-Guerin (BCG) immunotherapy.
- Trial name
- BRACE (NCT06990061)
- Testing
- Radiation therapy
- Where
- 3 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Locally Advanced Head and Neck Squamous Cell Carcinoma
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a multicenter, randomized, placebo-controlled, triple blind, phase II study to determine the efficacy and safety of xevinapant with radiotherapy in older patients with locally advanced head and neck squamous cell…
- Trial name
- RAVINA (NCT05724602)
- Testing
- Xevinapant
- Where
- 26 sites in Belgium, France and 8 more
- Volunteers
- 13 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Diagnosis of Cancer
Eortc MoBilE Device (EMBED)
This study is a longitudinal observational study that will investigate the feasibility of using mobile devices for the assessment of HRQoL and physical activity in adult cancer patients undergoing treatment.
- Trial name
- EMBED (NCT07711080)
- Volunteers
- 137 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Uveal Melanoma
Adjuvant Tebentafusp in High Risk Ocular Melanoma
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting.
- Trial name
- ATOM (NCT06246149)
- Testing
- Tebentafusp
- Where
- 15 sites in United States, Belgium and 7 more
- Volunteers
- 290 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer…
- Trial name
- SPECTA (NCT02834884)
- Testing
- RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen
- Where
- 136 sites in Austria, Belgium and 18 more
- Volunteers
- 4,975 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
NSCLC Stage IV
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
This is a multi-center, double-blind, placebo-controlled randomized phase II study to assess whether continuation of cemiplimab treatment (for up to 12 months) increases progression-free survival (PFS) as compared to placebo in…
- Trial name
- ICARS (NCT06219317)
- Testing
- Cemiplimab
- Where
- 12 sites in Belgium, France and 3 more
- Volunteers
- 136 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Meningioma
177Lu-DOTATATE for Recurrent Meningioma
Novel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation.
- Trial name
- LUMEN-1 (NCT06326190)
- Testing
- Local standard of Care, 177Lu-DOTATATE
- Where
- 19 sites in Austria, France and 4 more
- Volunteers
- 136 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
First Progression of Glioblastoma
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Despite comprehensive multimodal treatment of newly diagnosed glioblastoma, almost all patients suffer from tumour relapse. Currently, no standard of care exists to treat these tumour relapses.
- Trial name
- LEGATO (NCT05904119)
- Testing
- Lomustine, Reirradiation
- Where
- 45 sites in Austria, Belgium and 9 more
- Volunteers
- 411 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Clear Cell Renal Cell Carcinoma
Radiopharmaceutical Treatment of Advanced Kidney Cancer
Background This study is for adults with advanced kidney cancer that has spread to other parts of the body and has continued to progress despite treatment with immunotherapy and targeted therapy.
- Trial name
- RENALUT (NCT06783348)
- Testing
- 177Lu-PSMA-617
- Where
- 2 sites in France
- Volunteers
- 48 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non Small Cell Lung Cancer
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
This is a randomized, two-arm, comparative Phase II clinical trial designed to evaluate the difference in intracranial progression-free survival (iPFS) between two treatment strategies, assessed locally.
- Trial name
- NCT07234877
- Testing
- Ivonescimab, Carboplatin, Pemetrexed
- Where
- 26 sites in Austria, France and 6 more
- Volunteers
- 158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
NSCLC
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
The phase II APPLE trial gives the opportunity to prospectively validate liquid biopsies as a new standard for testing tumor progression compared with conventional radiological procedure in EGFR mutant advanced NSCLC patients.
- Trial name
- APPLE (NCT02856893)
- Testing
- Osimertinib, Gefitinib
- Where
- 23 sites in Belgium, France and 4 more
- Volunteers
- 156 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
This is a randomized open-label multicentre phase III superiority study of the effect of adding SABR to the standard of care treatment pembrolizumab on progression free survival in patients with oligometastases of a squamous cell…
- Trial name
- PROLoNg (NCT05815927)
- Testing
- Pembrolizumab, stereotattic ablation radiotherapy (SABR)
- Where
- 30 sites in Belgium, Italy and 2 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
The primary objective of the trial is to assess if GnRH antagonists in combination with external beam radiation therapy improve progression free survival (progression that can be biological, clinical, or death) compared to GnRH…
- Trial name
- PEGASUS (NCT02799706)
- Testing
- Degarelix, approved GnRH agonist, Radiotherapy
- Where
- 39 sites in Belgium, Denmark and 6 more
- Volunteers
- 885 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Thymoma Type B3, Thymic Carcinoma
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.
- Trial name
- NIVOTHYM (NCT03134118)
- Testing
- Nivolumab
- Where
- 20 sites in Belgium, France and 4 more
- Volunteers
- 55 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC